The FDA recently approved of a biosimilar (CT-P13) to infliximab, which is used for treating IBD patients, as well as patients suffering from rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. The new drug would be the first biosimilar monoclonal antibody approved in the United States. Dr. Edward Loftus, M.D., explains how biosimilars work, and discusses some of the issues surrounding this medication, and its potential benefits and drawbacks.
For more information about IBD, visit mayoclinic.org/IBD.
Dr. Loftus is a gastroenterologist at Mayo Clinic.